Oncoceutics Competitors and Similar CompaniesClear all
Oncoceutics's competitors and similar companies include Vivoryon Therapeutics, Moleculin Biotech, Werewolf Therapeutics and Shanghai Junshi Biosciences.
 Oncoceutics Oncoceutics is a drug discovery and development company focused on selective G protein-coupled receptor antagonists for oncology.
|  Vivoryon Therapeutics Vivoryon Therapeutics (previously known as Probiodrug) is a precision intervention company specializing in discovering and developing therapies for patients suffering from age-related diseases. |  Moleculin Biotech Moleculin Biotech is a pharmaceutical company focused on the development of anti-cancer drug candidates. |  Werewolf Therapeutics Werewolf Therapeutics is an oncology biotherapeutics company that develops cancer treatments designed to focus the body’s immune response to selectively target cancer. |  Shanghai Junshi Biosciences Shanghai Junshi Biosciences (上海君實生物醫藥科技) is a biopharmaceutical company focused on the treatment of cancer, autoimmune, and metabolic diseases. | |
Founding Date | Founding Date 2009 | Founding Date 1997 | Founding Date 2006 | Founding Date 2017 | Founding Date 2012 |
Type | Type Subsidiary | Type Public | Type Public | Type Public | Type Public |
Tags | |||||
Locations | Locations Philadelphia, US HQ | Locations Halle (Saale), DE HQ München, DE | Locations Houston, US HQ | Locations Cambridge, US HQ | Locations Shanghai, CN HQ |
Employees | Employees 12 | Employees 15 | Employees 1910% decrease | Employees 28 | Employees 2,5681% increase |
Valuation ($) | Valuation ($) N/A | Valuation ($) 69.8 m | Valuation ($) 7.5 m | Valuation ($) 118.9 m | Valuation ($) N/A |
Financial | |||||
Revenue (est.) | Revenue (est.) $5.2m (FY, 2019) | Revenue (est.) (€3.6m) (FY, 2023) | Revenue (est.) N/A | Revenue (est.) N/A | Revenue (est.) ¥1.5b (FY, 2023) |
Cost of goods | Cost of goods N/A | Cost of goods (€525k) (FY, 2023) | Cost of goods N/A | Cost of goods N/A | Cost of goods ¥541m (FY, 2023) |
Gross profit | Gross profit N/A | Gross profit (€2.6m) (FY, 2023) | Gross profit N/A | Gross profit N/A | Gross profit ¥941.9m (FY, 2023) |
Net income | Net income ($3.7m) (FY, 2019) | Net income (€28.3m) (FY, 2023) | Net income ($29.8m) (FY, 2023) | Net income ($37.4m) (FY, 2023) | Net income (¥2.5b) (FY, 2023) |
Funding | |||||
Total funding raised | Total funding raised N/A | Total funding raised N/A | Total funding raised $ 491k | Total funding raised $ 56m | Total funding raised N/A |
For sources of this data, please see the company profile
View Company Profiles
Vivoryon Therapeutics
HQ
Halle (Saale), DE
Employees
15
Vivoryon Therapeutics (previously known as Probiodrug) is a precision intervention company specializing in discovering and developing therapies for patients suffering from age-related diseases.
View companyMoleculin Biotech
HQ
Houston, US
Employees
19↓ 10% decrease
Moleculin Biotech is a pharmaceutical company focused on the development of anti-cancer drug candidates.
View companyWerewolf Therapeutics
HQ
Cambridge, US
Employees
28
Werewolf Therapeutics is an oncology biotherapeutics company that develops cancer treatments designed to focus the body’s immune response to selectively target cancer.
View companyShanghai Junshi Biosciences
HQ
Shanghai, CN
Employees
2,568↑ 1% increase
Shanghai Junshi Biosciences (上海君實生物醫藥科技) is a biopharmaceutical company focused on the treatment of cancer, autoimmune, and metabolic diseases.
View company